Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Vertex Ventures HC

Investor type Venture Capital

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 30
Average round size
info
The average size of a deal this fund participated in
$57M
Portfolio companies 20
Rounds per year 3.75
Lead investments 1
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.33
Exits 4
Key employees 2
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Health Care
  • Biotechnology
  • Medical Device
  • Therapeutics
  • Medical
Summary

The fund was located in North America if to be more exact in United States. The leading representative office of defined VC is situated in the Palo Alto.

Deals in the range of 10 - 50 millions dollars are the general things for fund. This Vertex Ventures HC works on 15 percentage points less the average amount of lead investments comparing to the other organizations. Considering the real fund results, this VC is 15 percentage points less often commits exit comparing to other organizations. The average startup value when the investment from Vertex Ventures HC is 50-100 millions dollars. The high activity for fund was in 2017. The top amount of exits for fund were in 2019. The fund is constantly included in 2-6 investment rounds annually.

Among the various public portfolio startups of the fund, we may underline Earlens Corporation, Obsidian Therapeutics, Twentyeight-Seven Therapeutics The fund has exact preference in a number of founders of portfolio startups. In case when startup counts 1 or 5+ of the founder, the chance for it to get the investment is meager. Among the most popular fund investment industries, there are Health Care, Health Diagnostics. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund.

The overall number of key employees were 2.

The typical case for the fund is to invest in rounds with 8-9 participants. Despite the Vertex Ventures HC, startups are often financed by Vertex Ventures, New Enterprise Associates, Versant Ventures. The meaningful sponsors for the fund in investment in the same round are Morgenthaler Ventures, Windham Venture Partners, Versant Ventures. In the next rounds fund is usually obtained by Vertex Ventures, Windham Venture Partners, New Enterprise Associates.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Vertex Ventures HC:
Typical Co-investors
Vertex Ventures HC is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Vertex Ventures HC:

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Adecco Glattbrugg, Switzerland, Zurich
BBH Capital Partners -
CDTI California, United States, Ventura
CVCC Zhongshi Capital China, Guangdong, Shenzhen
Enbridge Alberta, Calgary, Canada
FaciliTO -
Hoolai Games Beijing, Beijing, China
Huayue Machineries China, Shaanxi, Xian Shi
MTM Missouri, St Louis, United States
On Air Investments -
Quartet Ventures Australia, New South Wales, Sydney
Shengmei Guquan Touzi Jijin Guanli Beibei, China, Chongqing
Shenzhen Chunshang Capital China, Guangdong, Shenzhen
Techweek Chicago, Illinois, United States
The Startup Factory Durham, North Carolina, United States
VersoVentures Finland, Helsinki, Southern Finland
Virginia Founders Fund -
Xinruan Software -
Zhongkefuhua Innovation Investment Anhui, China, Kunshan

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Allay Therapeutics

Biotechnology
Medical
Therapeutics
$60M15 Sep 2021 Menlo Park, California, United States

Obsidian Therapeutics

Biotechnology
Health Care
Pharmaceutical
$115M09 Sep 2021 Cambridge, Massachusetts, United States

Sonoma BioTherapeutics

Biotechnology
Life Science
Therapeutics
$265M04 Aug 2021 South San Francisco, California, United States

NeuSpera Medical

Biopharma
Health Care
Medical Device
$65M20 Jul 2021 San Jose, California, United States

Elevation Oncology

Biopharma
Biotechnology
Health Care
Life Science
Pharmaceutical
$65M18 Nov 2020 New York, United States

Palleon Pharmaceuticals

Biotechnology
Health Care
Pharmaceutical
$100M17 Sep 2020 Massachusetts, United States

Elevation Oncology

Biopharma
Biotechnology
Health Care
Life Science
Pharmaceutical
$32M21 Jul 2020 New York, New York, United States

Epirium

Biopharma
Biotechnology
Health Care
Life Science
$85M19 Dec 2019 San Diego, California, United States

Cardero Therapeutics

Biotechnology
Health Care
Therapeutics
$85M18 Dec 2019 California, United States
News
Obsidian Therapeutics Closes $115M Series B Financing

– Obsidian Therapeutics, Inc. is a Cambridge, Mass.-based biotechnology company pioneering engineered cell and gene therapies.
– The company closed a $115m Series B financing.
– The round was led by The Column Group Crossover Fund (TCGX) with participation from RA Capital Management, Surveyor Capital (a Citadel company), Cowen Healthcare Investments, Deep Track Capital, Logos Capital, Pivotal BioVenture Partners, Samsara BioCapital, and Soleus Capital, and existing investors Atlas Venture, Vertex Ventures HC, Amgen Ventures, and Bristol Myers Squibb.
– Proceeds from the financing will be used to drive Obsidian’s lead tumor infiltrating lymphocyte (TIL) program, cytoTIL15, into the clinic and to first clinical data for the treatment of metastatic melanoma. In addition, the company plans to rapidly expand cytoTIL15 into multiple other solid tumor types and to advance its commercial manufacturing build.

Neuspera Medical Closes $65M Series C Equity Financing

– Neuspera Medical Inc. closed a $65m series C equity financing.
– The round was co-led by Vertex Ventures HC and Treo Ventures with participation from returning Series A and Series B investors Action Potential Venture Capital and Windham Venture Partners.
– The new funding will be used to conduct the SANS-UUI pivotal clinical study of its miniaturized implantable neuromodulation technology platform for use in subjects with Urinary Urgency Incontinence, a symptom of overactive bladder (OAB).

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Vertex Ventures HC?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: